A small Johns Hopkins pilot gave two psilocybin doses to 20 adults with chronic Lyme symptoms. Participants reported improved sleep and quality of life, and a 40% symptom drop at six months.

FDA officials outline a landmark regulatory framework for psychedelic drug development in the New England Journal of Medicine, focusing on depression and PTSD.

An in-depth look at ICPR 2026 research, clinical trial findings, regulatory hurdles, and implications for medical cannabis and patient care.